Stockreport

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc.  (SGMT) 
PDF Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant [Read more]